Genprex Inc Dossier
Qualitative Analysis
Business overview
Genprex, Inc. is a clinical-stage gene therapy company pioneering the development of gene-based therapies for large patient populations with significant unmet medical needs in oncology and diabetes. The company's proprietary oncology platform utilizes its systemic, non-viral ONCOPREX® Delivery System, which encapsulates tumor suppressor gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form to target cancer cells intravenously. Genprex's lead oncology drug candidate is REQORSA® Gene Therapy (quaratusugene ozeplasmid), which is being developed in combination with approved cancer therapies to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). In metabolic disease, Genprex is developing GPX-002 (Pdx1/MafA gene therapy), a pre-clinical diabetes gene therapy candidate designed to rejuvenate exhausted beta cells in Type 2 diabetes and transform pancreatic alpha cells into functional insulin-producing beta-like cells in Type 1 diabetes.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing clinical development resources on the most promising aspects of the Acclaim-1 and Acclaim-3 lung cancer clinical trials to support the most expeditious route to regulatory submissions.
Expected impact: Accelerates clinical validation of Reqorsa® Gene Therapy in combination with Tagrisso® and Tecentriq®.
Contemplated transfer of the diabetes clinical development program and GPX-002 assets into a new, wholly-owned subsidiary ('NewCo') to create a pure-play diabetes biopharmaceutical entity.
Expected impact: Unlocks the value of the novel diabetes program and expedites clinical development separate from oncology.
Transferring the manufacturing process of GPX-002 from academic collaborators to an experienced, integrated network of Contract Development and Manufacturing Organizations (CDMOs).
Expected impact: Enables clinical-scale production in a cGMP-compliant facility to accelerate IND-enabling preclinical studies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A new SRA entered in April 2026 to study biomarkers that may predict patient response to Reqorsa® Gene Therapy, building on a long-term collaborative relationship since 2010.
Terms: Not explicitly disclosed